The legal action, filed by Levi & Korsinsky, LLP, covers investors who purchased Embecta securities between November 25, 2025, and May 4, 2026. Plaintiffs contend that management reaffirmed unrealistic financial targets—including revenue growth and a 2.80 to 3.00 EPS range—even as the company faced mounting competitive share losses and shifting patient purchasing patterns. When the reality of the fiscal shortfall emerged, the company’s share price plummeted from 9.25 to 3.90.

The complaint argues that these performance gaps were not sudden market anomalies but foreseeable risks that leadership either ignored or failed to disclose. Beyond the revenue shortfall, Embecta slashed its quarterly dividend by 93%, from 0.15 to 0.01 per share, and cut its free cash flow projections by approximately half. Joseph E. Levi, representing the plaintiffs, maintains that the disparity between promised performance and actual results necessitates an investigation into what the company knew internally when it issued its fiscal guidance. The deadline for investors to petition the court to act as lead plaintiff is August 17, 2026.